PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
View analysts' price targets and recommendations, and compare them with competitors.
$11.07
Analysts expect the stock price to increase by 521.91%.
Buy
Positive consensus among analysts.
Analyze analyst forecasts for the company and compare them with competitors.
12.91M
Better than SAVA's estimated revenue of 0.
-2.58M
Worse than SAVA's estimated ebitda of 0.
-0.93
Worse than SAVA's estimated eps of 0.10.
-21.85M
Worse than SAVA's estimated net income of 4.19M.
-2.58M
Worse than SAVA's estimated ebit of 0.
478.53M
Worse than SAVA's estimated sg&a expense of 0.
Analyze DCF forecasts for the company and compare them with competitors.
1.14M
Better than SAVA's revenue of 0.00.
No Data
No DCF data available for this metric in the selected year.
-24.44M
Better than SAVA's ebitda of -31.85M.
-2136.36%
Worse than SAVA's ebitda margin of 100.00%.
-24.96M
Better than SAVA's ebit of -32.38M.
-2182.17%
Worse than SAVA's ebit margin of 100.00%.
524.00K
Better than SAVA's depreciation of 534.00K.
77.83M
Worse than SAVA's total cash of 233.44M.
6803.23%
Better than SAVA's cash as percentage of revenue of 100.00%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
5.54M
Better than SAVA's accounts payable of 7.13M.
483.83%
Worse than SAVA's payables as percentage of revenue of 100.00%.
-133.00K
Worse than SAVA's capital expenditure of -22.21M.
-11.63%
Better than SAVA's capex as percentage of revenue of 100.00%.
4.99%
Better than SAVA's weighted average cost of capital (wacc) of 5.34%.
5.02%
Better than SAVA's cost of equity of 5.34%.
4.08%
Better than SAVA's cost of debt of 4.40%.
-0.23
Worse than SAVA's beta of -0.58.
30.07M
Better than SAVA's diluted shares outstanding of 41.93M.
1.57M
Worse than SAVA's total debt of 0.00.
49.31M
Worse than SAVA's total equity of 101.06M.
50.89M
Worse than SAVA's total capital of 101.06M.
3.09%
Worse than SAVA's debt weighting of 0.00%.
96.91%
Worse than SAVA's equity weighting of 100.00%.
-24.77M
Better than SAVA's ebiat of -31.80M.
-23.19M
Better than SAVA's unlevered free cash flow of -47.27M.
2.00%
Equal to SAVA's long-term growth rate of 2.00%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
-71.33M
Worse than SAVA's net debt of -121.14M.
71.33M
Worse than SAVA's equity value of 112.01M.
2.37
Worse than SAVA's equity value per share of 2.67.